Heron Therapeutics (HRTX) Projected to Post Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Heron Therapeutics to post earnings of ($0.02) per share and revenue of $37.08 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Trading Up 1.3 %

Shares of HRTX opened at $2.33 on Tuesday. The stock’s 50 day moving average is $2.13 and its two-hundred day moving average is $1.79. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93. The firm has a market capitalization of $354.93 million, a PE ratio of -12.94 and a beta of 1.39.

Analyst Ratings Changes

A number of research firms recently commented on HRTX. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 8th. Needham & Company LLC reiterated a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a report on Friday, April 11th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.